J Korean Med Sci.  2024 Jul;39(26):e201. 10.3346/jkms.2024.39.e201.

Adverse Pregnancy and Child Outcomes in Oral Retinoid-Exposed Pregnancies: A Nationwide Population-Based Study

• You W
• Choi A
• Lee H
• Han JY
• Lee JH
• Shin JY

• KMID: 2557776
• DOI: http://doi.org/10.3346/jkms.2024.39.e201

Abstract

Background
Oral retinoids are used to treat various dermatological conditions, and their use is increasing in women of childbearing age. However, there is limited knowledge on the incidence of adverse outcomes after retinoid exposure during pregnancy. We aimed to evaluate the risk of adverse outcomes associated with oral retinoid exposure during pregnancy.
Methods
We conducted a retrospective cohort study using the NHIS mother-child linked healthcare database in South Korea. We included all women who gave live birth from April 1, 2009 to December 31, 2020 and their children. The exposure was defined as having ≥ 1 prescription of isotretinoin, alitretinoin, and acitretin from one month before pregnancy to the delivery. The outcomes of interest were adverse child outcomes including major congenital malformations, low birth weight, and neurodevelopmental disorders (autism spectrum disorder and intellectual disorder), and adverse pregnancy outcomes including gestational diabetes mellitus, preeclampsia, and postpartum hemorrhage. Propensity score-based matching weights were used to control for various potential confounders. For congenital malformation, low birth weight, and adverse pregnancy outcomes, we calculated relative risk (RR) with 95% confidence interval (CI) using a generalized linear model and for neurodevelopmental disorders, we estimated hazard ratio (HR) with 95% CI using the Cox proportional hazard model.
Results
Of 3,894,184 pregnancies, we identified 720 pregnancies (0.02%) as the oral retinoid-exposed group. The incidence of major congenital malformation was 400.6 per 10,000 births for oral retinoid-exposed group and 357.9 per 10,000 births for unexposed group and the weighted RR was 1.10 (95% CI, 0.65–1.85) in oral retinoid-exposed group compared with unexposed group. The neurodevelopmental disorder showed a potential increased risk, with the weighted HR of 1.63 (95% CI, 0.60–4.41) for autism spectrum disorder and 1.71 (95% CI, 0.60–4.93) for the intellectual disorder, although it did not reach statistical significance. For low birth weight and adverse pregnancy outcomes, no association was observed with oral retinoid exposure during pregnancy.
Conclusion
This study found no significantly increased risk of congenital malformations, autism spectrum disorders, and intellectual disability associated with oral retinoid exposure during pregnancy; however, given the limitations such as including only the live births and increased point estimate, potential risk cannot be fully excluded.

Keyword

Retinoids; Pregnancy; Adverse Child Outcomes; Adverse Pregnancy Outcomes

Figure

• 

  Fig. 1 Patterns of (A) oral retinoid usage, (B) isotretinoin usage, (C) alitretinoin usage, and (D) acitretin usage in the pregnant women.

• 

  Fig. 2 Annual trends in the prevalence of oral retinoid exposure among pregnant women.aTotal period is from one month before pregnancy to the day before the delivery date.bPre-pregnancy period is defined as one month before pregnancy to the day before the pregnancy starts.

Reference

1. Futoryan T, Gilchrest BA. Retinoids and the skin. Nutr Rev. 1994; 52(9):299–310. PMID: 7984345.

2. Pang ML, Murase JE, Koo J. An updated review of acitretin--a systemic retinoid for the treatment of psoriasis. Expert Opin Drug Metab Toxicol. 2008; 4(7):953–964. PMID: 18624682.

3. Durán CE, Riera-Arnau J, Abtahi S, Pajouheshnia R, Hoxhaj V, Gamba M, et al. Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis. Front Pharmacol. 2023; 14:1207976. PMID: 37663263.

4. Reinold J, Kollhorst B, Wentzell N, Platzbecker K, Haug U. Use of isotretinoin among girls and women of childbearing age and occurrence of isotretinoin-exposed pregnancies in Germany: a population-based study. PLoS Med. 2024; 21(1):e1004339. PMID: 38271295.

5. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med. 1985; 313(14):837–841. PMID: 3162101.

6. Melnik BC. Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol. 2017; 97(2):173–181. PMID: 27671426.

7. European Medicines Agency. Retinoid-containing medicinal products. Updated 2018. Accessed November 7, 2023. https://www.ema.europa.eu/en/medicines/human/referrals/retinoid-containing-medicinal-products .

8. iPLEDGE. Committed to pregnancy prevention. Accessed November 7, 2023. https://ipledgeprogram.com/#Main .

9. SORIATANE® (Acitretin) Capsules. Updated 2024. Accessed April 25, 2024. http://www.soriatane.com .

10. RetiCheck. Retinoid medication pregnancy prevention program. Updated 2023. Accessed November 7, 2023. http://reticheck.com/bbs/content.php?co_id=a01 .

11. Choi EJ, Han JY. Non-compliance with pregnancy prevention recommendations for isotretinoin in Korea between 2019–2020. Obstet Gynecol Sci. 2021; 64(2):201–208. PMID: 33752279.

12. Kamm JJ. Toxicology, carcinogenicity, and teratogenicity of some orally administered retinoids. J Am Acad Dermatol. 1982; 6(4):652–659. PMID: 7040511.

13. Kochhar DM, Penner JD, Tellone CI. Comparative teratogenic activities of two retinoids: effects on palate and limb development. Teratog Carcinog Mutagen. 1984; 4(4):377–387. PMID: 6149630.

14. Cheetham TC, Wagner RA, Chiu G, Day JM, Yoshinaga MA, Wong L. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol. 2006; 55(3):442–448. PMID: 16908350.

15. Bérard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007; 63(2):196–205. PMID: 17214828.

16. Barbero P, Lotersztein V, Bronberg R, Perez M, Alba L. Acitretin embryopathy: a case report. Birth Defects Res A Clin Mol Teratol. 2004; 70(10):831–833. PMID: 15470719.

17. Zomerdijk IM, Ruiter R, Houweling LM, Herings RM, Sturkenboom MC, Straus SM, et al. Isotretinoin exposure during pregnancy: a population-based study in The Netherlands. BMJ Open. 2014; 4(11):e005602.

18. Schaefer C, Meister R, Weber-Schoendorfer C. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet. 2010; 281(2):221–227. PMID: 19444462.

19. Cha EH, Kim N, Kwak HS, Han HJ, Joo SH, Choi JS, et al. Pregnancy and neonatal outcomes after periconceptional exposure to isotretinoin in Koreans. Obstet Gynecol Sci. 2022; 65(2):166–175. PMID: 35193174.

20. Recommendations for isotretinoin use in women of childbearing potential. Teratology. 1991; 44(1):1–6. PMID: 1957255.

21. Choi EJ, Kim N, Kwak HS, Han HJ, Chun KC, Kim YA, et al. The rates of major malformations after gestational exposure to isotretinoin: a systematic review and meta-analysis. Obstet Gynecol Sci. 2021; 64(4):364–373. PMID: 33757281.

22. Han JY, Nava-Ocampo AA, Koren G. Unintended pregnancies and exposure to potential human teratogens. Birth Defects Res A Clin Mol Teratol. 2005; 73(4):245–248. PMID: 15786494.

23. Yook JH, Han JY, Choi JS, Ahn HK, Lee SW, Kim MY, et al. Pregnancy outcomes and factors associated with voluntary pregnancy termination in women who had been treated for acne with isotretinoin. Clin Toxicol (Phila). 2012; 50(10):896–901. PMID: 23116253.

24. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med. 1995; 333(2):101–106. PMID: 7777014.

25. Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017; 46(3):799–800. PMID: 27794523.

26. Choi A, Noh Y, Jeong HE, Choi EY, Man KK, Han JY, et al. Association between proton pump inhibitor use during early pregnancy and risk of congenital malformations. JAMA Netw Open. 2023; 6(1):e2250366. PMID: 36626173.

27. Choi EY, Jeong HE, Noh Y, Choi A, Yon DK, Han JY, et al. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: a nationwide cohort study. PLoS Med. 2023; 20(2):e1004183. PMID: 36848338.

28. Noh Y, Jeong HE, Choi A, Choi EY, Pasternak B, Nordeng H, et al. Prenatal and infant exposure to acid-suppressive medications and risk of allergic diseases in children. JAMA Pediatr. 2023; 177(3):267–277. PMID: 36622684.

29. Nulman I, Berkovitch M, Klein J, Pastuszak A, Lester RS, Shear N, et al. Steady-state pharmacokinetics of isotretinoin and its 4-oxo metabolite: implications for fetal safety. J Clin Pharmacol. 1998; 38(10):926–930. PMID: 9807973.

30. Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernández-Díaz S. Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiol Drug Saf. 2013; 22(1):16–24. PMID: 22550030.

31. European Commission. EUROCAT: European network of population-based registries for the epidemiological surveillance of congenital anomalies. Updated 2023. Accessed November 7, 2023. https://eu-rd-platform.jrc.ec.europa.eu/eurocat/data-collection/guidelines-for-data-registration_en .

32. Pedersen CB, Mors O, Bertelsen A, Waltoft BL, Agerbo E, McGrath JJ, et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 2014; 71(5):573–581. PMID: 24806211.

33. Li L, Greene T. A weighting analogue to pair matching in propensity score analysis. Int J Biostat. 2013; 9(2):215–234. PMID: 23902694.

34. Yoshida K, Hernández-Díaz S, Solomon DH, Jackson JW, Gagne JJ, Glynn RJ, et al. Matching weights to simultaneously compare three treatment groups: comparison to three-way matching. Epidemiology. 2017; 28(3):387–395. PMID: 28151746.

35. Rönmark EP, Ekerljung L, Lötvall J, Wennergren G, Rönmark E, Torén K, et al. Eczema among adults: prevalence, risk factors and relation to airway diseases. Results from a large-scale population survey in Sweden. Br J Dermatol. 2012; 166(6):1301–1308. PMID: 22372948.

36. Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Solé M, Betriu-Bars A, Sanmartin-Novell V, Ortega-Bravo M, et al. Epidemiology of psoriasis. a population-based study. Actas Dermosifiliogr (Engl Ed). 2019; 110(5):385–392. PMID: 30587329.

37. Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008; 58(1):56–59. PMID: 17945383.

38. MacArthur C, Hansen M, Baynam G, Bower C, Kelty E. Trends in prenatal diagnosis of congenital anomalies in Western Australia between 1980 and 2020: a population-based study. Paediatr Perinat Epidemiol. 2023; 37(7):596–606. PMID: 37143205.

39. Ministry of Food and Drug Safety. Implementing a pregnancy prevention program for retinoid medications. Updated 2019. Accessed May 8, 2024. https://www.mfds.go.kr/brd/99/down.do?brd_id=ntc0021&seq=43375&data_tp=A&file_seq=2 .

40. Janesick A, Wu SC, Blumberg B. Retinoic acid signaling and neuronal differentiation. Cell Mol Life Sci. 2015; 72(8):1559–1576. PMID: 25558812.

41. Kubickova B, Martinkova S, Bohaciakova D, Nezvedova M, Liu R, Brozman O, et al. Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023; 487:153461. PMID: 36805303.

42. Maden M. Retinoid signalling in the development of the central nervous system. Nat Rev Neurosci. 2002; 3(11):843–853. PMID: 12415292.

43. Patraquim C, Silva A, Pereira Â, Gonçalves-Rocha M, Fernandes J, Pereira A. Isotretinoin embryopathy: report of one case. J Pediatr Neonatal Individ Med. 2015; 5(1):e050108.

44. Troncoso Sch M, Rojas H C, Bravo C E. Isotretinoin embryopathy. Report of one case. Rev Med Chil. 2008; 136(6):763–766. PMID: 18769834.

45. Schmitt-Hoffmann AH, Roos B, Sauer J, Spickermann J, Stoeckel K, Edwards D, et al. Pharmacokinetics, efficacy and safety of alitretinoin in moderate or severe chronic hand eczema. Clin Exp Dermatol. 2011; 36(Suppl 2):29–34.

46. Carretero G, Ribera M, Belinchón I, Carrascosa JM, Puig L, Ferrandiz C, et al. Guidelines for the use of acitretin in psoriasis. Actas Dermosifiliogr. 2013; 104(7):598–616. PMID: 23891453.